An interventional study of Patient-initiated shared care in Psoriasis, sponsored by University Hospital, Gentofte, Copenhagen. Completed at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-02-19.
Sponsored by University Hospital, Gentofte, Copenhagen · Not applicable, Interventional, and Supportive care
The primary objective of this research protocol is to evaluate the health related quality of life and efficacy of patient-initiated hospital follow-up for patients with moderate to severe psoriasis.
Psoriasis is a chronic inflammatory skin disease affecting 1 to 3% of the European population. Treatment of moderate to severe psoriasis often requires lifetime routine reviews by hospital dermatologist. Patterns of hospital review vary, but most patients attend follow-up every 12-16 week by dermatologist. At routine reviews the patient disease is often quiet and little intervention or no intervention is required, and times were the patient need help the time is limited for in-depth consultation. Both patient and healthcare professional requested more time. In-depth consultation is important in the care of psoriasis, because moderate to severe psoriasis has a significant impact on quality of life and patient have an increased incidence of cardiovascular risk factors such as hypertension, overweight, hyperlipidemia and exposure to tobacco and alcohol. These comorbidities and the psychosocial burden must be addressed by clinicians to help patients to acquire or to maintain competencies that are required to live with a chronic disease.
Patient-initiated hospital follow-up for patients with moderate to severe psoriasis might reduce inappropriate follow-up appointments, improve rapid access to specialist care and release resource to further in-depth consultation. If the patient is empowered to initiate hospital review thus patient's individual needs dictate the content, duration and contact with clinicians. It is our goal that an individual needs-based patient involvement in the shape of patient-initiated hospital follow-up,will be perceived as a benefit of the patients who 1) meets a high safety in the patient's own provision of medical treatment, 2) increase the patient's knowledge of the lifestyle and prevention of comorbidities and 3) strengths patient's overall satisfaction with treatment.
1,899 studies on the registry are indexed under Psoriasis; 233 are open to participants now.
This study's enrollment of 150 is above the median of 70 across 1,447 interventional studies indexed under Psoriasis.
Browse Psoriasis studies →University Hospital, Gentofte, Copenhagen is the lead sponsor of 154 studies on the registry; 9 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Patient-initiated shared care hospital reviews in which there were one planed hospital review every year and if needed additional reviews initiated by the patient. Access to nurse-run telephone helpline with direct access to a contact nurse.
Procedure: Patient-initiated shared care
Traditional, routine hospital reviews every three-fourth month.
Dermatology life quality index (DLQI)
Evaluation of quality of life
Time frame: 2 years
SF36 - Short Form 36 (SF-36)
Time frame: 2 years
Psoriasis Area and Severity Index (PASI
Time frame: 2 years
Hospital Anxiety and Depression Scale (HADS)
Time frame: 2 years
Body Image Scale (BIS)
Time frame: 2 years
Self-developed patient safety scale
Time frame: 2 years
Hospital visits
Time frame: 2 years
Numbers of phone calls to the nurse-run telephone helpline
Time frame: 2 years
Adherence to medicine treatment
Time frame: 2 years
Charlson Comorbidity Index
Time frame: 2 years
This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Gentofte, Copenhagen